GGrantIndex
← Leaderboards

Lawrence Michael Kauvar

Trellis Bioscience, Inc.

$27,642,215
Attributed
$27,642,215
Total exposure
12
Grants
12
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $4.5M · FY201124
$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$27,642,215 · 12

By mechanism

R44$17,934,271 · 5
SB1$5,995,892 · 2
U44$2,593,872 · 2
R43$893,234 · 2
R41$224,946 · 1

Top collaborators

No co-investigators on record.

Most similar at Trellis Bioscience, Inc.

Same institution · by research overlap

Others in their field

Top investigators on “Infection

Research focus

InfectionMonoclonal AntibodiesAffinityTherapeutic AntibodiesAntibodiesClinical TrialsProgramsTechnologyProteinsInnovationHuman Monoclonal AntibodiesFundingProductionToxicologyDoseCytomegalovirusBiological SciencesCostIn VitroEpitopesBindingSmall Business Innovation Research GrantCell BankRespiratory Syncytial Virus

Grant awards (32)

HCMV Therapeutic Antibody Safety Trial$998,144
U44 · FY2024 · AI · contact PI
Bacterial Pneumonia Therapeutic Antibody Safety Trial$297,917
U44 · FY2024 · AI · contact PI
HCMV Therapeutic Antibody Safety Trial$998,144
U44 · FY2023 · AI · contact PI
Strain-Independent Therapeutic Antibodies for Influenza$999,820
R44 · FY2022 · AI · contact PI
Biofilm disrupting antibody to treat respiratory and musculoskeletal infections$989,273
R44 · FY2022 · AI · contact PI
Strain-Independent Therapeutic Antibodies for Influenza$999,451
R44 · FY2021 · AI · contact PI
Therapeutic Antibody for RSV IIB$997,704
R44 · FY2021 · AI · contact PI
Biofilm disrupting antibody to treat respiratory and musculoskeletal infections$990,949
R44 · FY2021 · AI · contact PI
Therapeutic Antibody for RSV IIB$1,000,000
R44 · FY2020 · AI · contact PI
Strain-Independent Therapeutic Antibodies for Influenza$999,214
R44 · FY2020 · AI · contact PI
Biofilm disrupting antibody to treat respiratory and musculoskeletal infections$999,192
R44 · FY2020 · AI · contact PI
HCMV Therapeutic Antibody Safety Trial$299,667
U44 · FY2020 · AI · contact PI
Therapeutic Antibody for RSV IIB$1,000,000
R44 · FY2019 · AI · contact PI
Therapeutic Antibodies for Biofilm Infections$999,961
SB1 · FY2019 · AI · contact PI
Therapeutic Antibody for CMV$999,425
SB1 · FY2019 · AI · contact PI
Therapeutic Antibodies for Biofilm Infections$999,953
SB1 · FY2018 · AI · contact PI
Therapeutic Antibody for CMV$997,600
SB1 · FY2018 · AI · contact PI
Therapeutic antibody for RSV$1,499,589
R44 · FY2017 · AI · contact PI
Therapeutic Antibodies for Biofilm Infections$999,953
SB1 · FY2017 · AI · contact PI
Therapeutic Antibody for CMV$999,000
SB1 · FY2017 · AI · contact PI
Strain-Independent Therapeutic Antibodies for Influenza$981,301
R44 · FY2017 · AI · contact PI
Therapeutic antibody for RSV$1,268,751
R44 · FY2016 · AI · contact PI
Therapeutic Antibodies for Biofilm Infections$999,628
R44 · FY2016 · AI · contact PI
Strain-Independent Therapeutic Antibodies for Influenza$987,301
R44 · FY2016 · AI · contact PI
Therapeutic Antibodies for CMV$990,877
R44 · FY2015 · AI · contact PI
Strain-Independent Therapeutic Antibodies for Influenza$941,551
R44 · FY2015 · AI · contact PI
Therapeutic Antibodies for Biofilm Infections$224,946
R41 · FY2015 · AI · contact PI
Therapeutic Antibodies for CMV$990,935
R44 · FY2014 · AI · contact PI
Strain-Independent Therapeutic Antibodies for Influenza$298,735
R44 · FY2014 · AI · contact PI
Therapeutic Antibodies for Rabies$299,876
R43 · FY2012 · AI · contact PI
Therapeutic Antibodies for Bacteria$293,358
R43 · FY2012 · AI · contact PI
Therapeutic Antibodies for Bacteria$300,000
R43 · FY2011 · AI · contact PI